他汀类药物与伊布替尼联合治疗套细胞淋巴瘤绕过对伊布替尼耐药性

IF 0.2 Q4 MEDICINE, GENERAL & INTERNAL

Journal of Contemporary Medical Sciences Pub Date : 2023-06-26 DOI:10.22317/jcms.v9i3.1330

A. Al-Zebeeby, A. Abbas

{"title":"他汀类药物与伊布替尼联合治疗套细胞淋巴瘤绕过对伊布替尼耐药性","authors":"A. Al-Zebeeby, A. Abbas","doi":"10.22317/jcms.v9i3.1330","DOIUrl":null,"url":null,"abstract":"Objective: In this study, we report that a novel combination therapy of different statins with Ibrutinib can overcome such resistance.\nMethods: For this, we generated a cell line model, exhibiting resistance to Ibrutinib, by repeated exposure of mantle cell lymphoma cell line to Ibrutinib. Apoptosis was assessed by the extent of phosphatidylserine externalisation.\nResults: Our results indicated that resistance to Ibrutinib could be overcome by targeting a key enzyme, 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase in the cholesterogenesis pathway.\nConclusion: Reusing different statins in combination with Ibrutinib could improve therapy and enhance sensitivity to Ibrutinib mediated apoptosis.","PeriodicalId":42860,"journal":{"name":"Journal of Contemporary Medical Sciences","volume":" ","pages":""},"PeriodicalIF":0.2000,"publicationDate":"2023-06-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Statins in combination with Ibrutinib bypasses resistance to Ibrutinib in mantle cell lymphoma\",\"authors\":\"A. Al-Zebeeby, A. Abbas\",\"doi\":\"10.22317/jcms.v9i3.1330\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Objective: In this study, we report that a novel combination therapy of different statins with Ibrutinib can overcome such resistance.\\nMethods: For this, we generated a cell line model, exhibiting resistance to Ibrutinib, by repeated exposure of mantle cell lymphoma cell line to Ibrutinib. Apoptosis was assessed by the extent of phosphatidylserine externalisation.\\nResults: Our results indicated that resistance to Ibrutinib could be overcome by targeting a key enzyme, 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase in the cholesterogenesis pathway.\\nConclusion: Reusing different statins in combination with Ibrutinib could improve therapy and enhance sensitivity to Ibrutinib mediated apoptosis.\",\"PeriodicalId\":42860,\"journal\":{\"name\":\"Journal of Contemporary Medical Sciences\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":0.2000,\"publicationDate\":\"2023-06-26\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Contemporary Medical Sciences\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.22317/jcms.v9i3.1330\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"MEDICINE, GENERAL & INTERNAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Contemporary Medical Sciences","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.22317/jcms.v9i3.1330","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}

引用次数: 0

摘要

目的：在本研究中，我们报道了一种新的不同他汀类药物与伊布替尼的联合治疗可以克服这种耐药性。方法：为此，我们通过反复将套细胞淋巴瘤细胞系暴露于伊布替尼，建立了对伊布替尼有耐药性的细胞系模型。通过磷脂酰丝氨酸外化的程度来评估细胞凋亡。结果：我们的结果表明，通过靶向胆固醇生成途径中的关键酶3-羟基-3-甲基戊二酰辅酶a（HMG-CoA）还原酶，可以克服对伊布替尼的耐药性。结论：将不同的他汀类药物与伊布替尼联合使用，可以改善治疗效果，提高对伊布替尼介导的细胞凋亡的敏感性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Statins in combination with Ibrutinib bypasses resistance to Ibrutinib in mantle cell lymphoma

Objective: In this study, we report that a novel combination therapy of different statins with Ibrutinib can overcome such resistance. Methods: For this, we generated a cell line model, exhibiting resistance to Ibrutinib, by repeated exposure of mantle cell lymphoma cell line to Ibrutinib. Apoptosis was assessed by the extent of phosphatidylserine externalisation. Results: Our results indicated that resistance to Ibrutinib could be overcome by targeting a key enzyme, 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase in the cholesterogenesis pathway. Conclusion: Reusing different statins in combination with Ibrutinib could improve therapy and enhance sensitivity to Ibrutinib mediated apoptosis.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Journal of Contemporary Medical Sciences MEDICINE, GENERAL & INTERNAL-

自引率

0.00%

发文量

审稿时长

12 weeks